Randomized trial on the effect of non-calcium-containing phosphate binder lanthanum carbonate on vascular calcification in hemodialysis patients

INTERVENTION: Lanthanum carbonate treatment (Enrollment: 1 year, Follow‐up: 3 years, Extension period: 2 years) Calcium carbonate treatment ((Enrollment: 1 year, Follow‐up: 3 years, Extension period: 2 years) CONDITION: end‐stage renal disease PRIMARY OUTCOME: Abdominal aortic calcification (Progression of abdominal aortic calcification volume detected by computed tomography image for renal carcinoma screening) SECONDARY OUTCOME: 1) Phosphorus and calcium level achievement rate as defined by the Japanese Society for Dialysis Therapy guideline ; 2) Incidence of hypercalcemia ( defined as corrected serum calcium>10.5mg/dl); 3) Incidence of secondary hyperparathyroidism (defined as i‐PTH>240pg/ml); 4) Performance rate of PTx and PEIT; 5) BAP(ALP), i‐PTH, BAP/i‐PTH; 6) Arterial stiffness change (CAVI, PWV, ABI); 7) Safety INCLUSION CRITERIA: 1) Hemodialysis patients 2) SerumP>6.0mg/dl and taking Phosphate binder in Hyperphosphosphataemia. 3) Hemodialysis for more than 6 mo, less than 5 years 4) Men or women >=20 years of age 5) Patients with written IC